Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

May 31, 2025

Conditions
Solid Tumors
Interventions
DRUG

Retroviral vector-transduced autologous T cells to express anti-ALPP CARs

Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered

Trial Locations (1)

400037

RECRUITING

Department of Oncology, Xinqiao Hospital, Chongqing

All Listed Sponsors
collaborator

TCRCure Biopharma Ltd.

INDUSTRY

lead

Xinqiao Hospital of Chongqing

OTHER